ID26965A - MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS - Google Patents

MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS

Info

Publication number
ID26965A
ID26965A IDW20002095A ID20002095A ID26965A ID 26965 A ID26965 A ID 26965A ID W20002095 A IDW20002095 A ID W20002095A ID 20002095 A ID20002095 A ID 20002095A ID 26965 A ID26965 A ID 26965A
Authority
ID
Indonesia
Prior art keywords
breast cancer
aromatase
medicine
prevent
treat breast
Prior art date
Application number
IDW20002095A
Other languages
Indonesian (id)
Inventor
Alfred Schmidt
Heinrich Wieland
Original Assignee
S W Patentverwertungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8231611&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID26965(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S W Patentverwertungs Gmbh filed Critical S W Patentverwertungs Gmbh
Publication of ID26965A publication Critical patent/ID26965A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The use of estrogen formation inhibitor(s) (I) is claimed for the preparation of a topical medicament for the prophylaxis and/or treatment of breast cancer.
IDW20002095A 1998-03-18 1999-03-03 MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS ID26965A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98104949A EP0943333A1 (en) 1998-03-18 1998-03-18 Medicament for the prevention and/or treatment of breast cancer comprising an inhibitor of estrogen synthesis

Publications (1)

Publication Number Publication Date
ID26965A true ID26965A (en) 2001-02-22

Family

ID=8231611

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002095A ID26965A (en) 1998-03-18 1999-03-03 MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS

Country Status (19)

Country Link
EP (2) EP0943333A1 (en)
JP (1) JP4920822B2 (en)
KR (1) KR100778803B1 (en)
CN (1) CN1168448C (en)
AT (1) ATE230995T1 (en)
AU (1) AU751040B2 (en)
BR (1) BR9908885A (en)
CA (1) CA2324077C (en)
CZ (1) CZ292643B6 (en)
DE (1) DE59904042D1 (en)
DK (1) DK1063998T3 (en)
ES (1) ES2190201T3 (en)
HU (1) HU226105B1 (en)
ID (1) ID26965A (en)
IL (1) IL138292A (en)
PL (1) PL343100A1 (en)
RU (1) RU2225206C2 (en)
SK (1) SK285349B6 (en)
WO (1) WO1999047143A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042411A1 (en) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermal therapeutic system for the delivery of exemestane
DE10054294A1 (en) * 2000-11-02 2002-05-16 Heinrich Wieland Topical treatment for mastalgia
RU2297798C1 (en) * 2005-10-03 2007-04-27 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук ГУ НИИ онкологии ТНЦ СО РАМН Method for complex treatment of resectable forms of endometrial cancer
RU2363466C2 (en) * 2007-03-29 2009-08-10 АО Ефаг Method and set for treating and preventing malignant tumours of female reproductive system using 9-oxoacridine-10-acetic acid, and/or salt thereof and/or ester thereof
JP4524296B2 (en) * 2007-03-30 2010-08-11 生化学工業株式会社 Hair growth promoter
DE102007032468A1 (en) 2007-07-10 2009-01-15 Brätter, Christian, Dr. Transdermal therapeutic systems containing the active substance anastrozole
RU2396942C2 (en) * 2008-08-01 2010-08-20 Владимир Борисович Деев Medicinal composition for treatment of benign neoplasms on skin
KR20140040690A (en) * 2011-01-31 2014-04-03 루콜라스-엠.디. 리미티드 Cosmetic use
US11850451B2 (en) 2011-01-31 2023-12-26 Lucolas-M.D. Ltd. Cosmetic compositions and methods for improving skin conditions
EP2648721B1 (en) * 2011-01-31 2018-09-19 LUCOLAS-M.D. Ltd. Combinations of aromatase inhibitors and antioxidants
EP3666276A1 (en) * 2018-12-14 2020-06-17 dcic Biopharmaceutical Limited Medication against estrogen-receptor beta (erbeta) positive breast tumor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235893A (en) * 1978-05-08 1980-11-25 Brodie Angela M Ester derivatives of 4-hydroxy-4-androstene-3,17-dione and a method for inhibiting estrogen biosynthesis
DE3322285A1 (en) * 1983-06-18 1984-12-20 Schering AG, 1000 Berlin und 4709 Bergkamen 1-ALKYL-ANDROSTA-1,4-DIEN-3,17-DIONE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
FR2558373B1 (en) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre ANTI-ESTROGEN MEDICINAL PRODUCT BASED ON 4-HYDROXYTAMOXIFENE FOR PERCUTANEOUS ADMINISTRATION
JPS6345294A (en) * 1986-04-07 1988-02-26 Shionogi & Co Ltd Aromatase-inhibiting steroid derivative
EP0310542B1 (en) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagenic and antioestrogenic compounds for the treatment of hormone-dependent tumours
GB2231568B (en) * 1989-03-31 1992-07-08 Farmos Oy New aromatase inhibiting 4(5)-imidazoles
GB2229719B (en) * 1989-03-30 1992-04-29 Farmos Oy Novel aromatase inhibiting 4(5)-imidazoles
FR2656310B1 (en) * 1989-12-22 1992-05-07 Roussel Uclaf NEW STEROUID PRODUCTS COMPRISING IN POSITION 10, A SUBSTITUTED THIOETHYL RADICAL, THEIR PREPARATION METHOD AND THE INTERMEDIATES THEREOF, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE4039559A1 (en) * 1990-12-07 1992-06-11 Schering Ag FUNCTIONALIZED VINYLAZOLES, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THIS VINYLAZOLES AND THE USE THEREOF FOR THE PRODUCTION OF MEDICINAL PRODUCTS
GB9212833D0 (en) * 1992-06-17 1992-07-29 Glaxo Group Ltd Chemical compounds
DE69427289T2 (en) * 1993-03-16 2001-09-06 Pfizer Inc., New York NAPHTAL DERIVATIVES
JPH07215992A (en) * 1993-12-07 1995-08-15 Teikoku Hormone Mfg Co Ltd 6- or 7-substituted androsta-1,4-diene derivative
DE69519582D1 (en) * 1994-09-14 2001-01-11 Univ Sheffield CONTROL OF HAIR GROWTH
US5780050A (en) * 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
ATE200978T1 (en) * 1996-03-29 2001-05-15 S W Patentverwertungs Ges M B COSMETICS OR COSMETIC COMPOSITION FOR SMOOTHING AND TIGHTENING THE SKIN IN DISTURBED SUBKINUM CONNECTIVE FAT TISSUE, PARTICULARLY IN CASE OF CELLULITE
CA2632790A1 (en) * 1996-07-22 1998-01-29 Renovo Limited Use of sex steroid function modulators to treat wounds and fibrotic disorders

Also Published As

Publication number Publication date
SK285349B6 (en) 2006-11-03
AU3143499A (en) 1999-10-11
CA2324077A1 (en) 1999-09-23
CN1168448C (en) 2004-09-29
IL138292A (en) 2005-08-31
ES2190201T3 (en) 2003-07-16
EP1063998B1 (en) 2003-01-15
ATE230995T1 (en) 2003-02-15
SK13422000A3 (en) 2001-05-10
BR9908885A (en) 2000-11-21
CZ292643B6 (en) 2003-11-12
EP1063998A1 (en) 2001-01-03
RU2225206C2 (en) 2004-03-10
PL343100A1 (en) 2001-07-30
WO1999047143A1 (en) 1999-09-23
HU226105B1 (en) 2008-04-28
DE59904042D1 (en) 2003-02-20
CN1301165A (en) 2001-06-27
JP2002506823A (en) 2002-03-05
CA2324077C (en) 2008-07-29
EP0943333A1 (en) 1999-09-22
IL138292A0 (en) 2001-10-31
KR20010034603A (en) 2001-04-25
DK1063998T3 (en) 2003-05-12
JP4920822B2 (en) 2012-04-18
KR100778803B1 (en) 2007-11-27
AU751040B2 (en) 2002-08-08
CZ20003256A3 (en) 2001-04-11
HUP0101005A2 (en) 2001-08-28

Similar Documents

Publication Publication Date Title
PL365285A1 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
BR0315597A (en) Low-dose processes for treating disorders where tnf (alpha) activity is harmful
BR9908592A (en) Process for inhibiting the activity of 17ß-hydroxysteroid dehydrogenase type 5, pharmaceutical composition, 17ß-hydroxysteroid dehydrogenase type 5 inhibitor, process for inhibiting 17ß-hydroxysteroid dehydrogenase type 3, 17ß-hydroxysteroid dehydrogenase type 3, processes to treat, or reduce the risk of developing, prostate cancer, benign prostatic hyperplasia, acne, seborrhea, hirsutism or androgenic alopecia, polycystic ovary syndrome, breast cancer, endometriosis or leiomyoma, to inhibit testicular hormone secretions, to treat early puberty, and, kit
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
BR9806060A (en) Compound, pharmaceutical composition and processes to treat a patient suffering from a sick condition, to inhibit factor xa, and to inhibit thrombin formation.
BR0207316A (en) Epothilone derivatives for the treatment of refractory tumors
MXPA04000654A (en) Dermal therapy using phosphate derivatives of electron transfer agents.
BR9509006A (en) Composition for topical application to the skin pharmaceutical composition use of a cholesterol synthesis inhibitor and process for the treatment of mitigation or prevention of skin disorders
ID26965A (en) MEDICINE TO PREVENT AND / OR TREAT BREAST CANCER, WHICH CONTAINS AROMATASE STEROID INHIBITORS
BG100510A (en) Method of treating androgenic alopecia with 5-alpha reductase inhibitors
MY164077A (en) Compositions and uses of et743 for treating cancer
GB0020504D0 (en) Therapeutic method
SE9803761D0 (en) Method to avoid increased iridial pigmentation during prostaglandin treatment
AU2003250190A1 (en) Combination of an aromatase inhibitor with a bisphosphonate
HUP9901505A2 (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
DE60030107D1 (en) VITAMIN-D DERIVATIVES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATODES
NZ511559A (en) Use of staurosporine derivatives for treating ocular neovascular diseases
PT986393E (en) USING A NITROXIDE OR ITS PRO-PHARMACY IN THE CANCER'S PROFILACTIC AND THERAPEUTIC TREATMENT
BR0115215A (en) Method for treating inflammation
ATE293972T1 (en) TREATMENT OF CHRONIC PAIN
PL367707A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
BR0111740A (en) Tumor combination therapy comprising substituted acrylamoyl distamycin derivatives and alkylating agents
RU94044457A (en) Use of benzthiophenes for hirsutism and alopecia inhibition
BR0315374A (en) Organic compounds
NZ337048A (en) Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer